KRAS and familial pancreatic carcinoma: Oncogenic activation of RAS due to missense mutations is frequently detected in several types of cancer, including pancreatic cancer.53 Given that mutations in one RAS protein isoform, KRAS, are found in nearly 90% of pancreatic cancers, RAS signaling appears to play a critical role in both pancreatic cancer initiation and maintenance.